Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Biodesix (BDSX) Equity Average (2020 - 2025)

Historic Equity Average for Biodesix (BDSX) over the last 6 years, with Q3 2025 value amounting to -$292000.0.

  • Biodesix's Equity Average fell 10091.08% to -$292000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$292000.0, marking a year-over-year decrease of 10091.08%. This contributed to the annual value of $12.7 million for FY2024, which is 107.2% up from last year.
  • As of Q3 2025, Biodesix's Equity Average stood at -$292000.0, which was down 10091.08% from $6.1 million recorded in Q2 2025.
  • Over the past 5 years, Biodesix's Equity Average peaked at $38.8 million during Q1 2021, and registered a low of -$4.2 million during Q3 2023.
  • Its 5-year average for Equity Average is $12.8 million, with a median of $12.6 million in 2023.
  • In the last 5 years, Biodesix's Equity Average tumbled by 27699.24% in 2023 and then surged by 356377.44% in 2025.
  • Quarter analysis of 5 years shows Biodesix's Equity Average stood at $17.9 million in 2021, then crashed by 50.49% to $8.9 million in 2022, then crashed by 82.3% to $1.6 million in 2023, then surged by 1454.98% to $24.4 million in 2024, then crashed by 101.2% to -$292000.0 in 2025.
  • Its last three reported values are -$292000.0 in Q3 2025, $6.1 million for Q2 2025, and $16.0 million during Q1 2025.